The use of breast imaging for predicting response to  neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO

To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial.

Source: European Journal of Cancer - December 8, 2017 Category: Cancer & Oncology Authors: S. Di Cosimo, C. Campbell, H.A. Azim, G. Galli, G. Bregni, G. Curigliano, C. Criscitiello, M. Izquierdo, L. de la Pena, D. Fumagalli, L. Fein, J. Vinholes, W.M.J. Ng, M. Colleoni, A. Ferro, B.J. Naume, A. Patel, J. Huober, M.J. Piccart-Gebhart, J. Baselga Tags: Original Research Source Type: research